NCT04199169View on ClinicalTrials.gov

Safety and Immunogenicity of a Nipah Virus Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

February 18, 2020

Primary Completion Date

May 6, 2022

Study Completion Date

May 6, 2022

Conditions
Nipah Virus Infection
Interventions
BIOLOGICAL

HeV-sG-V

A Hendra virus soluble glycoprotein vaccine formulated in phosphate buffer and adjuvanted with aluminum hydroxide. Placebo is normal saline.

BIOLOGICAL

Normal Saline Placebo

0.9% Saline

Trial Locations (1)

45229

Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati

Sponsors

Lead Sponsor

Auro Vaccines LLC
All Listed Sponsors
collaborator

PATH

OTHER

collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

collaborator

Cincinnati Children's Hospital Medical Center (CCHMC)

UNKNOWN

lead

Auro Vaccines LLC

INDUSTRY

NCT04199169 - Safety and Immunogenicity of a Nipah Virus Vaccine | Biotech Hunter | Biotech Hunter